Twist inks collaboration deal with Adicet Bio

By The Science Advisory Board staff writers

September 13, 2021 -- Twist Bioscience and Adicet Bio will collaborate on the discovery and development of gamma delta T-cell cancer therapies.

The companies will develop immune cells with human chimeric antigen receptors and T-cell receptors aimed at disease-specific cell surface antigens, Twist said. Twist will contribute its proprietary single-chain fragment variable and VHH nanobody technologies from its library, which will support Adicet's discovery of new chimeric antigen receptors to generate novel gamma delta CAR T-cell products.

Adicet will pay Twist an upfront licensing fee as well as clinical and regulatory milestone payments and royalties.


Copyright © 2021 scienceboard.net
 
To access all The ScienceBoard content create a free account now:


Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.


Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
 
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.

Already have an account? Sign in here